SEARCH

SEARCH BY CITATION

References

  • 1
    Johnsson H. Anticoagulant therapy can be safer: an active follow-up and written care programs reduce the number of complications. Läkartidningen 1999; 96: 338890 [in Swedish].
  • 2
    Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: and inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 4238.
  • 3
    Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 68791.
  • 4
    Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 68791.
  • 5
    Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002; 347: 96974.
  • 6
    Engström G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographical distribution of stroke incidence within an urban population. Relationships to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke 2001; 32: 1098103.
  • 7
    Franke CL, de Jonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21: 72630.
  • 8
    Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16: 5538.
  • 9
    Ericsson SE, Link H. Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit. Acta Neurol Scand 1983; 68: 96106.
  • 10
    Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study BMJ 2002; 325: 10735.
  • 11
    van Walraven C, Hart RG, Singer DE et al. Oral anticoagulation vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 24418.
  • 12
    Fogelholm R, Eskola K, Kiminkinen T, Kunnamo I. Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neur Neurosurg 1992; 55: 11214.
  • 13
    Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26: 14717.
  • 14
    Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001; 11: 195200.
  • 15
    Sjöblom L, Hårdemark HG, Lindgren A et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy. A Swedish multicenter study. Stroke 2001; 32: 256774.
  • 16
    Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
  • 17
    Segal JB, McNamara RL, Miller MR et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
  • 18
    Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve protheses. Circulation 1994; 89: 63541.
  • 19
    Merlo J, Lindblad U, Pessah-Rasmussen H et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000; 16: 23543.
  • 20
    August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab 1999; 84: 18626.
  • 21
    Giardina EG. Heart disease in women. Int J Fertil 2000; 45: 3507.
  • 22
    Hendricks AS, Goodman B, Stein JH, Carnes M. Gender differences in acute myocardial infarction: the University of Wisconsin experience. WMJ 1999; 98: 303.
  • 23
    Eriksson H, Wåhlander K, Lundström T, Billing Clason S, Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor Ximegalatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomised, placebo-controlled trial. Blood 2002; 100: 81a (abstract no. 297).